Licensing Negotiations to M&A Deals in the Life Sciences Industry

Senior associate Adam Falconi will speak at the LES 2022 Annual Meeting, taking place in San Francisco from October 16–19.

Adam will speak on October 17 at 2:30 p.m. on the panel “Licensing Negotiations to M&A Deals in the Life Sciences”. The panel, comprising strategic advisors and biopharmaceutical industry leaders with extensive experience managing life sciences deals, will present and discuss research findings which seem to suggest that the majority of life sciences acquisitions start out as licensing discussions.

The panel will also delve into strategic considerations that both prospective sellers/licensors and buyers/licensees should consider when pursuing these life sciences transactions. The panel will discuss the ramifications of these findings and consider questions such as:

• Why are most biopharma companies “bought, not sold”? Why may it be advantageous to let acquirers drive the transaction?
• How many suitors should a biopharma looking to sell or out-license IP have? How should it navigate this process?
• What are the typical milestone events and timelines for successful biopharma transactions? How should you time your outreach for a licensing or M&A transaction relative to a data readout, and when should you pivot? What are the advantages of starting with a licensing negotiation?
• Are these licensing vs. M&A considerations different for private and public companies? Are these licensing vs. M&A considerations different for platform vs. pipeline companies?

You can learn more on the LES website.